No Data
No Data
Editas Medicine (NASDAQ:EDIT) Investors Are Sitting on a Loss of 90% If They Invested Three Years Ago
Synthetic Immunology Market Report 2024 With Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks With Highest Upside Potential?
SeqWell Launches Loaded-transposase Portfolio to Support Expanding Use of NGS-based Gene Editing Analysis Methods
Tagify off-the-shelf and custom loaded-transposase reagents provide reliability and scalability to tagmentation-based on- & off-target gene editing analysisBEVERLY, Mass.--(BUSINESS WIRE)--#NGS--seqWe
Shareholders in Editas Medicine (NASDAQ:EDIT) Have Lost 87%, as Stock Drops 17% This Past Week
It's not possible to invest over long periods without making some bad investments. But really bad investments should be rare. So consider, for a moment, the misfortune of Editas Medicine, Inc. (NASD
Unveiling 5 Analyst Insights On Editas Medicine
Throughout the last three months, 5 analysts have evaluated Editas Medicine (NASDAQ:EDIT), offering a diverse set of opinions from bullish to bearish.